Last reviewed · How we verify
vemurafenib + HD IL-2
Vemurafenib inhibits mutant BRAF kinase to block tumor cell proliferation, while high-dose IL-2 activates the immune system to enhance anti-tumor immunity.
Vemurafenib inhibits mutant BRAF kinase to block tumor cell proliferation, while high-dose IL-2 activates the immune system to enhance anti-tumor immunity. Used for Metastatic melanoma with BRAF V600E mutation.
At a glance
| Generic name | vemurafenib + HD IL-2 |
|---|---|
| Also known as | Proleukin |
| Sponsor | Clinigen, Inc. |
| Drug class | BRAF inhibitor + cytokine immunotherapy |
| Target | BRAF V600E kinase; IL-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Vemurafenib is a selective BRAF V600E inhibitor that directly targets the oncogenic mutation common in melanoma, blocking the MAPK signaling pathway. High-dose IL-2 (interleukin-2) is a cytokine that stimulates T-cell and natural killer cell proliferation and activation, enhancing the body's anti-tumor immune response. The combination aims to leverage both targeted therapy and immunotherapy for improved efficacy in BRAF-mutant melanoma.
Approved indications
- Metastatic melanoma with BRAF V600E mutation
Common side effects
- Pyrexia (fever)
- Chills
- Fatigue
- Nausea
- Cutaneous squamous cell carcinoma
- Capillary leak syndrome (IL-2 related)
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |